CCR2 and breast cancer: The utilization of cationic polymeric NPs carrying CCR2 siRNA could block the expression level of CCR2 in monocytes, suppress monocyte recruitment in tumor tissues, and enhance anti-tumor effects in the breast cancer model [43].